Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety

Jun 27 2011

• By Sue Sutter

Related Content

Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned

Jun 18 2009

Vandetanib Shows Heightened FDA Focus On Dose Optimization For Cancer Drugs

Dec 06 2010

Novartis Has Proof Of Concept For New R&D Model, And NMEs To Show It

Dec 08 2008

Ilaris Safety Data Inadequate For Gout Indication, FDA Panel Says

Jun 21 2011

Novartis' Ilaris For Gout: FDA Questions Whether Symptom Relief Is Worth Risks

Jun 17 2011

Novartis Gambles Priority Review Voucher On <i>Ilaris</i> Gout Indication

Jun 27 2011

COPD Drug Dose Selection May Face Greater Scrutiny In <i>Arcapta</i>’s Wake

Mar 14 2011

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window